Skip to content
Back to meeting Original
Mark Wildgust (he/him)· @MAWildgust · X·· 3 days agoScore45

JNJ-6143

Body

Thrilled for @BGarmezy to present updated results for JNJ-6143. @JNJInnovMed team are excited about these results and the potential to provide patients with more tomorrows and better today’s. Exciting MOA, “first in class molecule”. #esmo26 #mycompany

19 views · 1 like · 0 reposts · 0 replies

引用@
Thrilled to share updated results from JNJ-6143, the AR-BRD4 RIPTAC therapy, presented by @BGarmezy. Totally novel MOA was well tolerated, oral pill and produced significant benefit for pts (PSA90 50%, ORR 68%). P2 trial active now and more coming. Lots of potential!
在 X 查看被引用的帖子

Source: Mark Wildgust (he/him) · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.